Idera Pharmaceuticals Inc  

(Public, NASDAQ:IDRA)   Watch this stock  
Find more results for IDRA
+0.06 (3.57%)
Feb 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.65 - 1.79
52 week 1.19 - 3.33
Open 1.68
Vol / Avg. 0.00/835,298.00
Mkt cap 266.09M
P/E     -
Div/yield     -
EPS -0.42
Shares 147.65M
Beta 2.53
Inst. own 33%
Mar 8, 2017
Q4 2016 Idera Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -3994.74% -19500.00%
Operating margin -4017.65% -19616.87%
EBITD margin - -19420.88%
Return on average assets -81.05% -67.58%
Return on average equity -93.32% -76.47%
Employees 62 -
CDP Score - -


167 Sidney St
CAMBRIDGE, MA 02139-4237
United States - Map
+1-617-6795500 (Phone)
+1-617-6795592 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company's drug candidates include IMO-8400; IMO-2125/IMO-2055, and IMO-9200. The Company's TLR antagonist lead drug candidates are IMO-8400 and IMO-9200, which are both antagonists of TLR7, TLR8 and TLR9. Its TLR agonist lead drug candidates are IMO-2055 and IMO-2125, which are both agonists of TLR9.

Officers and directors

James A. Geraghty Independent Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Vincent J. Milano President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Youssef El Zein Independent Vice Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Louis J. Arcudi III Chief Financial Officer, Senior Vice President - Operations, Treasurer, Secretary
Age: 54
Bio & Compensation  - Reuters
Robert Clayton Fletcher Senior Vice President - Business Development and Strategic Planning
Age: 52
Bio & Compensation  - Reuters
Joanna C. Horobin M.D. Senior Vice President, Chief Medical Officer
Age: 61
Bio & Compensation  - Reuters
Robert A. Doody Jr. Vice President - Investor Relations and Corporate Communications
Bio & Compensation  - Reuters
William S. Reardon CPA Lead Independent Director
Age: 69
Bio & Compensation  - Reuters
Sudhir Agrawal D. Phil. Director, President of Research
Age: 61
Bio & Compensation  - Reuters
Maxine Gowen Ph.D. Director
Age: 57
Bio & Compensation  - Reuters